Bimagrumab: the muscle-building drug studied with GLP-1s

The striking trial finding is recomposition: participants gained muscle mass while losing fat mass. That is unusual, because losing weight almost always means losing some muscle too, the exact worry our GLP-1 muscle-loss guide covers for the class.

One consequence is that the scale can understate the change: if muscle goes up while fat goes down, the number may move modestly even as body composition improves substantially. It is a reminder that the scale is a blunt instrument, and that quality of loss, not just quantity, is what shapes health and how a result holds.

The most-watched bimagrumab work combines it with semaglutide (the BELIEVE trial). The logic is complementary: semaglutide drives strong fat loss but takes some muscle with it, and bimagrumab is designed to protect or build muscle. Together, the hope is weight loss that is more fat and less lean tissue than a GLP-1 alone achieves.

If that pans out, it points toward a future where GLP-1 weight loss is paired with a muscle-protecting agent, addressing one of the class's real drawbacks. It is a promising idea in testing, not an established regimen.

Reported side effects have included mild muscle-related effects (such as muscle spasms or transient discomfort) and occasional diarrhea. Being a different drug class, it does not carry the GLP-1 gut-and-appetite side-effect signature.

It is early-stage, so the full safety profile is still forming, and larger trials will characterize it. Its dosing is also different: an infusion or injection on its own schedule rather than a self-administered weekly pen.

Because bimagrumab works differently from the incretins, its caution profile is its own and still being defined, rather than the familiar pancreatitis-gallbladder-thyroid list of the GLP-1 class.

The market caution applies as it does to any investigational drug: bimagrumab is not available by prescription, and anything sold under the name outside a trial is unregulated and unsafe.

Bimagrumab is investigational, with its combination work advancing through trials. It represents a genuinely different angle on the muscle-loss problem, and its future may be as a partner to GLP-1 therapy rather than a standalone.

For now, the way to protect muscle during GLP-1 weight loss is the proven one, available today: a protein floor and resistance training, covered in our muscle-loss guide. Whatever the future adds, those habits stay foundational, and DoseLog keeps them tracked.